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In the present study, we report on the full range of physical diseases acquired by survivors of Hodgkin lymphoma diagnosed
in adolescence or young adulthood. In a Danish nationwide population-based cohort study, 1,768 five-year survivors of Hodg-
kin lymphoma diagnosed at ages 15–39 years during 1943–2004 and 228,447 comparison subjects matched to survivors on
age and year of birth were included. Hospital discharge diagnoses and bed-days during 1977–2010 were obtained from the
Danish Patient Register for 145 specific disease categories gathered in 14 main diagnostic groups. The analysis was con-
ducted separately on three subcohorts of survivors, that is, survivors diagnosed 1943–1976 for whom we had no information
on rehospitalisation for Hodgkin lymphoma and survivors diagnosed 1977–2004, split into a subcohort with no expected
relapses and a subcohort for whom a rehospitalisation for Hodgkin lymphoma indicated a relapse. The overall standardised
hospitalisation rate ratios (RRs) were 2.0 [95% confidence interval (CI), 1.9–2.1], 1.5 (1.4–1.6) and 2.9 (2.6–3.1) respectively,
and the corresponding RRs for bed-days were 3.5 (3.4–3.5), 1.8 (1.8–1.9) and 10.4 (10.3–10.6). Highest RRs were seen for
nonmalignant haematological conditions (RR: 2.6; 3.1 and 9.7), malignant neoplasms (RR: 3.2; 2.5 and 4.7) and all infections
combined (RR: 2.5; 2.2 and 5.3). Survivors of Hodgkin lymphoma in adolescence or young adulthood are at increased risk for
a wide range of diseases that require hospitalisation. The risk depends on calendar period of treatment and on whether the
survivors were rehospitalised for Hodgkin lymphoma, and thus likely had a relapse.
The age-speciﬁc incidence of Hodgkin lymphoma shows a
bimodal distribution, with a ﬁrst peak in adolescence and young
adulthood and a second peak after the age of 55 years.1 As
Hodgkin lymphoma is one of the few cancers with a peak in
incidence at ages 15–39 years, this cancer is of special interest in
adolescent and young adult oncology.2 Hodgkin lymphoma
diagnosed during adolescence or young adulthood is usually of
the nodular sclerosis subtype, in contrast to cases diagnosed at
older ages,3 and the biology of cancer in adolescents and young
adults in general has been suggested to be different from that of
cancers in children and older people.4,5 Studies of patients in
this speciﬁc age range are, therefore, important.6,7
Hodgkin lymphoma is a cancer with excellent survival.
Recent ﬁve-year relative survival in Sweden was 96% for
patients whose cancer was diagnosed when they were 18 to
29-year old, and 95% for those aged 30–39 years.8 The treat-
ment of Hodgkin lymphoma may, however, carry a lifelong
risk of late effects.9,10 Selected late effects in survivors of
Hodgkin lymphoma diagnosed during adolescence or young
adulthood have been studied, including second malignant
neoplasms,11 cardiovascular disease12 and diabetes.13
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In a previous publication, we reported on the risk of hos-
pitalisation among survivors of adolescent and young adult
cancer in general.14 In the present nationwide study, com-
prising 1,768 ﬁve-year survivors of Hodgkin lymphoma diag-
nosed at the age of 15–39 years and 228,447 comparison
subjects, we provide detailed information on their long-term
relative and absolute excess risks of all types of physical
diseases requiring inpatient care.
Material and Methods
Hodgkin lymphoma survivor and comparison cohorts
All 2,515 individuals diagnosed with Hodgkin lymphoma
(International Classiﬁcation of Diseases [ICD]-7: 201; ICD-O,
third edition: 9650/3–9667/3; ICD-10: C81) as a ﬁrst primary
cancer (apart from nonmelanoma skin cancer), diagnosed at
age 15–39 years, notiﬁed to the Danish Cancer Registry in
the period January 1, 1943 to December 31, 2009, and who
were alive on April 2, 1968 (start of the Danish civil registra-
tion system) were identiﬁed.15,16 For each cancer patient, ﬁve
population-based comparison subjects were selected random-
ly from the civil registration system, who were alive without
cancer on the date of diagnosis of the corresponding cancer
patient (in the following, referred to as the index date) and
of the same sex and year of birth. Information on migration
and vital status during follow-up was obtained from the civil
registration system. We excluded those who had died or emi-
grated within ﬁve years of the date of cancer diagnosis, or an
equivalent lag period for the comparison subjects, and those
who had died or emigrated before the start of the Patient
Register on January 1, 1977. These exclusions resulted in a
cohort of 1,861 ﬁve-year survivors of Hodgkin lymphoma
and 237,875 population comparison subjects (Fig. 1).
Hospital admissions for physical diseases
The Danish National Patient Register holds information on
all hospital admissions for nonpsychiatric illnesses in Den-
mark since January 1, 1977.17 Registration is mandatory, and
diagnostic information is submitted electronically by treating
physicians. Each admission to hospital initiates a record
which includes the personal identiﬁcation number of the
patient, dates of admission and discharge, a primary dis-
charge diagnosis and supplementary diagnoses coded accord-
ing to ICD-8 until 1993 and according to ICD-10 thereafter.
Details of cohort members were linked to the Patient Reg-
ister, and a full hospital history with discharge diagnoses and
numbers of bed-days spent in hospital was established for
each person recorded as having had a hospital admission.
Individuals who had ever been hospitalised for a congenital
malformation or chromosome abnormality (ICD-8,
7402 759, ICD-10, Q002Q99) were excluded, as we judged
that these disorders might confound any causal association
between cancer treatment and chronic disorders. Thus, 1,768
ﬁve-year survivors of Hodgkin lymphoma in adolescence or
young adulthood and 228,447 population comparison sub-
jects were left for risk analysis (Fig. 1).
To characterize and quantify the burden of diseases
requiring hospitalisation in detail, we grouped the hospital
discharge diagnoses into 145 speciﬁc disease categories (see
Supporting Information Table S1). As the Patient Register
does not reliably distinguish hospitalisation for relapse of a
primary cancer from hospitalisation for a second primary
cancer, we obtained information from the Danish Cancer
Registry on second primary cancers among survivors and on
ﬁrst primary cancers among comparison subjects.
In order to take the effect of treatment for relapse of
Hodgkin lymphoma into account in the analyses, the cohort
of Hodgkin lymphoma survivors was split into the following
three subcohorts: (1) survivors diagnosed during 1943–1976
for whom we did not have complete information on rehospi-
talisations for Hodgkin lymphoma, since the Patient Register
started in 1977 (early mixed subcohort; n5 494); (2) survi-
vors diagnosed during 1977–2004 for whom we cannot iden-
tify any rehospitalisations in a department of oncology or
haematology with a primary diagnosis of Hodgkin lymphoma
either at least a year after the initial Hodgkin lymphoma
diagnosis, or six months to one year after the initial diagnosis
in combination with a date of death within ten years from
diagnosis (primary treatment only subcohort; n5 887), (3)
survivors diagnosed during 1977–2004 for whom there is a
registration of a rehospitalisation for Hodgkin lymphoma as
deﬁned above (assumed relapse subcohort; n5 387; Table 1).
We emphasize that the 1977–2004 subcohort stratiﬁcation is
based entirely on the available inpatient information.
In our analysis, we did not include diagnoses indicating
symptoms and ill-deﬁned diseases, or injuries and violence,
as these were regarded as too nonspeciﬁc and primarily due
to external causes, respectively. Neither did we include the
sections on mental disorders and pregnancy-related diseases
and complications, as these conditions require special consid-
eration and will be addressed in separate publications.
What’s new?
Excellent survival rates for Hodgkin lymphoma have allowed increasing numbers of patients to enjoy a normal, disease-free
life expectancy. Nonetheless, for some, premature death remains a concern, owing to the risk of late effects, including second
malignant neoplasms, from curative therapy. The authors of the present study quantified the burden of new diagnoses in
Hodgkin lymphoma survivors, showing that among 1,768 five-year survivors diagnosed in adolescence or young adulthood
from 1943 to 2004, a significant proportion later suffered conditions requiring hospitalisation. Malignant neoplasms, infec-
tions and circulatory diseases accounted for the majority of new diagnoses.
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Statistical analysis
Follow-up of study subjects began ﬁve years after diagnosis
of Hodgkin lymphoma (or after the index date for compari-
son subjects) or on January 1, 1977 (when the Danish Patient
Register was initiated) if this was later. Follow-up ended on
the earliest of date of death, date of emigration or December
31, 2010, which was the date of the latest update of the
Patient Register. Only the primary diagnosis, i.e. the main
reason for hospitalisation for each inpatient admission, was
considered in the analyses.
For analyses of new diagnoses, only the ﬁrst hospital
admission for each of the 145 speciﬁc disease categories was
considered but, for analyses of the number of bed-days spent
in hospital, all hospital admissions for the disease category
were included. For each disease category, the observed num-
ber of new diagnoses among all the survivors of Hodgkin
lymphoma was divided by the expected number derived from
the appropriate sex-, age- and calendar period-speciﬁc diag-
nosis rates for the comparison subjects to obtain the rate
ratio for new diagnoses (RR diagnoses). The corresponding
95% conﬁdence interval (CI) was obtained assuming a Pois-
son distribution. Rate ratios for bed-days spent in hospital
(RR bed-days) were obtained in a similar fashion. Absolute
excess rates per 10,000 person-years at risk for new diagnoses
and bed-days (AER diagnoses & AER bed-days) were derived
as the difference between the observed and expected rates for
each disease category, and 95% CIs were obtained, again
assuming a Poisson distribution.
The observed and expected numbers for the 145 speciﬁc
disease categories were also summed to obtain RRs and
AERs for broader diagnostic groups, including 14 main diag-
nostic groups based on the Chapters of the ICD. In the ICD
a considerable number of infections are classiﬁed with
diseases of the organ they affect, rather than in the chapter
speciﬁcally headed ‘Infections’. Therefore, we included an
additional broad disease grouping labelled ‘All infections’ that
brought together all diagnoses indicating an infection, irre-
spective of their position in the ICD.
For 94% of patients included in the cohort, the Cancer
Registry record speciﬁed the intended use of radiotherapy as
part of ﬁrst-line treatment only on a yes/no level. For survi-
vors included in the primary treatment only subcohort, we
speciﬁed for risk estimates in patients with (n5 338) and
without intended use of radiotherapy (n5 494). The Danish
Cancer Registry does not contain reliable information on
treatment with chemotherapy.
All statistical analyses were performed with SAS software
version 9.3.
Results
By the end of the follow-up period, 514 (29%) of the 1,768
ﬁve-year survivors of Hodgkin lymphoma and 41,012 (18%)
of the 228,447 comparison subjects had died. The survivors
were followed in the Patient Register for a total of 27,310
person-years (median 14.4 years, range, 0.1 to 34.0 years).
879 (50%) survivors were followed up for at least 20 years
after diagnosis, and 412 (23%) for at least 30 years. Charac-
teristics of the Hodgkin lymphoma survivor group are shown
in Table 1.
Total numbers of new diagnoses and bed-days
During follow-up, the 494 ﬁve-year survivors included in the
early mixed subcohort had a total of 1,519 new diagnoses
belonging to one of the 145 speciﬁc disease categories listed
in Supporting Information Table S1, whereas only 758 new
diagnoses were expected, resulting in a signiﬁcantly increased
Figure 1. Flow chart showing exclusions from the cohort of adolescent or young adult Hodgkin lymphoma patients and exclusions from the
population comparison cohort.
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overall RR of 2.0. The corresponding RRs for survivors diag-
nosed in 1977–2004 were 1.5 and 2.9, respectively, for those
without and with readmission to hospital for Hodgkin lym-
phoma (Table 2). The absolute excess rates (AERs) for new
diagnoses were 682 per 10,000 person-years in the early
mixed subcohort and 217 and 855 per 10,000 person-years,
respectively in the 1977–2004 primary treatment only and
the assumed relapse subcohorts.
For all three subcohorts, the AERs for new diagnoses tended
to increase with increasing attained age, while there was little
such trend for the RRs (Table 2; Supporting Information Fig.
S1, panels A–C). The AERs as well as the RRs for bed-days
varied markedly between the three subcohorts of survivors,
with the highest estimates in the 1977–2004 assumed relapse
subcohort (Table 2). Table 2 and Supporting Information Fig-
ure S1, panel D–F gives the bed-days by attained age.
Table 1. Characteristics of 1,768 five-year survivors of adolescent or young adult Hodgkin lymphoma diagnosed in Denmark, 1943–2004
Characteristic Both sexes (%) Men (%) Women (%)
Total 1,768 (100) 1,014 (57.4) 754 (42.6)
Number of person–years 27,310 (100) 15,300 (56.0) 12,010 (44.0)
Age at Hodgkin lymphoma diagnosis (years)
15219 282 (16.0) 171 (16.9) 111 (14.7)
20224 415 (23.5) 224 (22.1) 191 (25.3)
25229 448 (25.3) 246 (24.3) 202 (26.8)
30234 335 (18.9) 194 (19.1) 141 (18.7)
35239 288 (16.3) 179 (17.7) 109 (14.5)
Subcohorts of Hodgkin lymphoma survivors
Diagnosed in 194321976:
Early mixed1 494 (27.9) 270 (26.6) 224 (29.7)
Diagnosed in 197722004:
Primary treatment only2 887 (50.2) 498 (49.1) 389 (51.6)
Assumed relapse3 387 (21.9) 246 (24.3) 141 (18.7)
Years since Hodgkin lymphoma diagnosis
5–9 1,768 (100) 1,014 (100) 754 (100)
10–19 1,470 (83.1) 840 (82.8) 630 (83.6)
20–29 879 (49.7) 492 (48.5) 387 (51.3)
30–39 412 (23.3) 214 (21.1) 198 (26.3)
40–49 115 (6.5) 57 (5.6) 58 (7.7)
50–59 21 (1.2) 13 (1.3) 8 (1.1)
Attained age (years)4
20–29 620 (35.1) 355 (35.0) 265 (35.1)
30–39 1,328 (75.1) 731 (72.1) 577 (76.5)
40–49 1,314 (74.3) 760 (75.0) 554 (73.5)
50–59 763 (43.2) 421 (41.5) 342 (45.4)
60–69 345 (19.5) 184 (18.1) 161 (21.4)
70–79 78 (4.4) 41 (4.0) 37 (4.9)
Type of censoring
End of follow-up (December 31, 2010) 1,233 (69.7) 690 (68.0) 543 (72.0)
Death 514 (29.1) 314 (31.0) 200 (26.5)
Emigration 21 (1.2) 10 (1.0) 11 (1.5)
1No information on rehospitalisations available.
2No rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncological or haematological department one year or more after the first
Hodgkin lymphoma diagnosis or, if rehospitalised for Hodgkin lymphoma 6 months to one year after the first Hodgkin lymphoma diagnosis, did not
die within 10 years after the first Hodgkin lymphoma diagnosis.
3Rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncologic or haematologic department one year or more after the first Hodgkin
lymphoma diagnosis, or rehospitalisation 6 months to one year after the first Hodgkin lymphoma diagnosis and deceased within 10 years of the first
Hodgkin lymphoma diagnosis.
4Number at entry into category.
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Table 2. Rate ratios (RRs) and absolute excess rates (AERs) with corresponding confidence intervals (CIs) for the three subcohorts of five-year survivors of Hodgkin lymphoma diagnosed in
adolescence or young adulthood; estimates are given for the total, gender and attained age
Survivors diagnosed with Hodgkin
lymphoma 1943–1976
Survivors of Hodgkin lymphoma
diagnosed 1977–2004
Early mixed
subcohort1
Primary treatment
only subcohort2
Assumed relapse
subcohort3
No. of
survivors
RR
(95% CI)
AER5
(95% CI)
No. of
survivors RR (95% CI)
AER5
(95% CI)
No. of
survivors RR (95% CI)
AER5
(95% CI)
NEW DIAGNOSES4
Total 494 2.0 (1.9–2.1) 682 (614–751) 887 1.5 (1.4–1.6) 217 (168–265) 387 2.9 (2.6–3.1) 855 (751–960)
Gender
Men 270 2.1 (2.0–2.3) 744 (649–839) 498 1.6 (1.5–1.8) 265 (200–329) 246 3.1 (2.8–3.4) 872 (742–1.003)
Women 224 1.9 (1.7–2.0) 612 (513–711) 389 1.3 (1.2–1.4) 156 (83–229) 141 2.6 (2.3–2.9) 826 (653–999)
Attained age6 (years)
20–29 139 2.0 (1.4–2.8) 351 (110–592) 330 1.3 (1.0–1.7) 90 (223–203) 151 2.7 (2.1–3.6) 537 (305–770)
30–39 347 1.6 (1.4–1.9) 259 (150–367) 691 1.5 (1.3–1.7) 179 (105–252) 290 2.6 (2.2–3.0) 588 (437–738)
40–49 413 1.8 (1.6–2.0) 403 (300–506) 626 1.2 (1.1–1.3) 93 (20–167) 275 3.0 (2.6–3.4) 962 (782–1,142)
50–59 372 2.4 (2.2–2.6) 954 (810–1,097) 280 1.7 (1.5–2.0) 499 (332–667) 111 3.1 (2.6–3.7) 1,455 (1,090–1,819)
60–69 249 2.3 (2.1–2.5) 1,373 (1,126–1,620) 75 2.4 (1.9–3.0) 1,515 (937–2,093) 21 2.9 (1.9–4.4) 2,018 (693–3,342)
70–79 75 1.6 (1.3–1.9) 1,028 (509–1,547) 3 – – – – –
BED-DAYS
Total 494 3.5 (3.4–3.5) 20,520 (20,205–
23,836)
887 1.8 (1.8–1.9) 3,384 (3,226–
3,542)
387 10.4 (10.3–10.6) 37,070 (36,489–
37,652)
Gender
Men 270 3.7 (3.7–3.8) 21,948 (21,507–
22,389)
498 2.1 (2.0–2.2) 4,299 (4,077–
4,521)
246 10.1 (9.9–10.3) 34,826 (34,113–
35,539)
Women 224 3.2 (3.1–3.2) 18,899 (18,448–
19,350)
389 1.5 (1.5–1.6) 2,217 (1,995–
2,438)
141 11.0 (10.8–11.2) 40,848 (39,850–
41,845)
Attained age6 (years)
20–29 139 8.1 (7.6–8.5) 22,193 (20,762–
23,625)
330 1.4 (1.3–1.6) 787 (496–
1,078)
151 23.3 (22.5–24.2) 47,017 (45,256–
48,777)
30–39 347 5.5 (5.4–5.7) 19,603 (18,958–
20,247)
691 2.1 (2.0–2.2) 3,111 (2,872–
3,350)
290 14.9 (14.5–15.2) 39,799 (38,800–
40,797)
40–49 413 3.7 (3.6–3.8) 16,843 (16,333–
17,354)
626 1.5 (1.4–1.6) 2,090 (1,850–
2,331)
275 9.7 (9.5–10.0) 37,384 (36,418–
38,351)
50–59 372 3.8 (3.7–3.9) 24,534 (23,887–
25,181)
280 2.0 (1.9–2.1) 6,717 (6,154–
7,280)
111 4.0 (3.8–4.2) 19,866 (18,582–
21,149)
Cancer Epidemiology
2
2
3
6
H
o
sp
ita
lisa
tio
n
s
a
m
o
n
g
su
rvivo
rs
o
f
H
o
d
g
k
in
lym
p
h
o
m
a
In
t.
J.
C
a
n
ce
r:
1
4
0
,
2
2
3
2
–
2
2
4
5
(2
0
1
7
)
V C
2
0
1
7
Th
e
A
u
th
o
rs
In
te
rn
a
tio
n
a
l
Jo
u
rn
a
l
o
f
C
a
n
ce
r
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s
Ltd
o
n
b
e
h
a
lf
o
f
U
IC
C
Specific diseases and diagnostic groups
The extent of the proportional increases in the rate of new
diagnoses varied substantially between the 14 main diagnostic
groups, with the largest values seen for nonmalignant haema-
tological conditions, malignant neoplasms, all infections com-
bined, diseases of the respiratory system and diseases of the
circulatory system. Rate ratios for these main diagnostic
groups are shown in Figure 2, panel A for each of the three
subcohorts.
The AERs for new diagnoses revealed a somewhat different
pattern. The largest AERs were for diseases of the circulatory
system, which accounted for between 23% and 38% of all
excess new diagnoses, followed by malignant neoplasms, dis-
eases of the respiratory system and diseases of the digestive
organs, while nonmalignant haematological conditions
accounted for <5% of the excess new diagnoses (Table 3 and
Fig. 2, panel B). As many of the disease entities of the respira-
tory system are infections, all infections combined was a major
cause of hospitalisation accounting for between 14% and 30%
of the excess diagnoses in the respective subcohorts. Diseases
of the circulatory system, all infections combined and malig-
nant neoplasms explained together between 61% and 78% of
the excess inpatient disease pattern among survivors (Table 3).
Table 4 gives further details regarding the 145 speciﬁc dis-
ease categories and shows that the rate ratio for hospitalisa-
tion for all types of infections combined was signiﬁcantly
higher in the assumed relapse subcohort (RR, 5.3) than in
the early mixed subcohort (RR, 2.5) or the primary treatment
only subcohort (RR, 2.2). We did a separate analysis of the
rate ratios of hospitalisation for infections prior to the Hodg-
kin lymphoma diagnosis. Interestingly, this analysis showed a
modest increase in risk from birth to three years prior to the
diagnosis of Hodgkin lymphoma (RR, 1.4, 95% CI, 1.1–1.8)
and a more marked increase in the three-year period preced-
ing the diagnosis (2.4; 1.5–3.8). The latter ﬁnding likely
reﬂects the consequences of a yet undiagnosed Hodgkin lym-
phoma on the immune system or disorders of the immune
system or other diseases that could lead to Hodgkin lympho-
ma or that have a shared aetiology.
Among the speciﬁc disease categories, the highest AERs
were seen for aortic valve disorders, acute myocardial infarc-
tion, angina pectoris, heart failure, chronic ischaemic heart
disease, pneumonia, cancers of the breast, respiratory system
and digestive organs and sepsis (Table 4). The AERs for
malignant neoplasms and heart diseases tended to be highest
in the early mixed cohort, while the AERs for infections
tended to be highest in the 1977–2004 assumed relapse sub-
cohort. Results for all 145 speciﬁc diseases are shown in Sup-
porting Information Table S2.
The largest RRs for bed-days were for malignant neo-
plasms, nonmalignant haematological conditions, diseases of
the respiratory system, diseases of the circulatory system and
all infections; all with signiﬁcant heterogeneity between the
three subcohorts of Hodgkin lymphoma survivors. In general,Ta
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Figure 2. (a) Rate ratios (RRs) for diagnoses for selected main diagnostic groups with estimates for each of the three subcohorts. (b) Abso-
lute excess rates (AERs) for diagnoses for selected main diagnostic groups per 10,000 person-years for each of the three subcohorts. The
total AERs (not included in the plot) were:- for those diagnosed 1943–1976 (i.e., early mixed subcohort): 682, 95% CI, 614–751; for those
diagnosed 1977–2004 and with no rehospitalisations (i.e., primary treatment only subcohort): 217, 95% CI, 168–265; for those diagnosed
1977–2004 and with rehospitalisations (i.e., assumed relapse subcohort): 855, 95% CI, 751–960. [Color figure can be viewed at wileyonli-
nelibrary.com]
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Table 3. Absolute excess rates (AERs) with corresponding 95% confidence intervals (CIs) and percentage of total AER for each of the 14 main diagnostic groups for survivors of Hodgkin
lymphoma diagnosed during 1943–1976 and for survivors diagnosed during 1977–2004 with primary treatment only or with assumed relapse
Survivors of Hodgkin lymphoma
diagnosed 1943–1976
Survivors of Hodgkin lymphoma
diagnosed 1977–2004
Early mixed
subcohort1
Primary treatment
only subcohort2
Assumed relapse
subcohort3
Main diagnostic group AER4 (95% CI) % of total AER AER4 (95% CI) % of total AER AER4 (95% CI) % of total AER
Circulatory system 259 (221–297) 38.0 66 (44–88) 30.4 201 (153–249) 23.5
Malignant neoplasms 122 (97–147) 17.9 39 (24–54) 18.0 86 (56–116) 10.1
Respiratory system 95 (72–118) 13.9 42 (25–59) 19.4 179 (137–222) 20.9
Digestive organs 61 (37–85) 8.9 210 (226–6) 4.6 101 (62–141) 11.8
Infections 35 (21–49) 5.1 25 (12–37) 11.5 86 (57–116) 10.1
Endocrine system 31 (17–45) 4.5 10 (0–20) 4.6 30 (10–50) 3.5
Benign and in situ neoplasms 18 (5–31) 2.6 25 (13–38) 11.5 2 (212–15) 0.2
Nervous system and sense organs 18 (6–30) 2.6 10 (0–20) 4.6 25 (6–45) 2.9
Nonmalignant haematological conditions 12 (4–20) 1.8 10 (3–17) 4.6 39 (20–57) 4.6
Skin and subcutaneous tissue 12 (2–22) 1.8 6 (24–15) 2.8 24 (5–43) 2.8
Urinary system and genital organs 10 (29–29) 1.5 7 (29–22) 3.2 53 (22–84) 6.2
Eye 8 (0–16) 1.2 2 (23–7) 0.9 21 (27–5) 20.1
Musculoskeletal and connective tissue 4 (211–20) 0.6 214 (227–1) 26.5 28 (1–55) 3.3
Ear and mastoid 23 (26–1) 20.4 0 (24–4) 0.0 2 (26–9) 0.2
Total 682 (614–751) 100.0 217 (168–265) 100.0 855 (751–960) 100.0
Special calculation for infections
Infections classified in other ICD–chapters5 58 (40–76) 8.5 40 (24–55) 18.4 146 (107–184) 17.1
All infections6 93 (70–116) 13.6 64 (44–84) 29.5 232 (183–280) 27.1
1No information on rehospitalisations available.
2No rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncological or haematological department one year or more after the first Hodgkin lymphoma diagnosis or, if rehospitalised
for Hodgkin lymphoma 6 months to one year after the first Hodgkin lymphoma diagnosis, did not die within 10 years after the first Hodgkin lymphoma diagnosis.
3Rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncologic or haematologic department one year or more after the first Hodgkin lymphoma diagnosis, or rehospitalisation 6
months to one year after the first Hodgkin lymphoma diagnosis and deceased within 10 years of the first Hodgkin lymphoma diagnosis.
4Absolute excess rate per 10,000 person-years; the rates are standardised for age, sex and calendar periods.
5From Nervous system and sense organs: bacterial meningitis, encephalitis, myelitis and encephalomyelitis and intracranial and intraspinal abscess; from Circulatory system: Acute and subacute
endocarditis; from Respiratory system: Acute upper respiratory infections, pneumonia, other acute lower respiratory infections, bronchitis, abscess of lung and pleural empyema; from Digestive
organs: acute peritonitis; from Skin and subcutaneous tissue: cutaneous abscess, furuncle and carbuncle, cellulitis, other infections of skin and subcutaneous tissue; from Musculoskeletal and con-
nective tissue: infectious arthropathies, from Urinary and genital organs: cystitis.
6The sum of infections classified in the ICD chapter ‘Infections’ and infections classified in other ICD chapters.
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Table 4. The cohort of 1,768 five-year survivors of Hodgkin lymphoma diagnosed in adolescence or young adulthood divided into three subcohorts
Survivors of Hodgkin lymphoma
diagnosed 1943–1976
Survivors of Hodgkin lymphoma
diagnosed 1977–2004
Early mixed
subcohort1
Primary treatment
only subcohort2
Assumed relapse
subcohort3
No. of
new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
No. of
new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
No. of new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
Total 1,519 2.0 (1.9–2.1) 682 (614–751) 805 1.5 (1.4–1.6) 217 (168–265) 614 2.9 (2.6–3.1) 855 (751–960)
Infections 63 2.6 (2.0–3.3) 35 (21–49) 53 2.1 (1.6–2.8) 25 (12–37) 50 5.1 (3.9–6.7) 86 (57–116)
 Sepsis 13 3.0 (1.7–5.2) 8 (1–14) 16 5.5 (3.3–9.0) 11 (5–18) 16 14.7 (9.0–24.1) 32 (15–49)
Malignant neoplasms 197 3.2 (2.8–3.7) 122 (97–147) 75 2.5 (2.0–3.1) 39 (24–54) 51 4.7 (3.6–6.2) 86 (56–116)
 Digestive organs 34 2.9 (2.1–4.1) 20 (10–31) 13 3.1 (1.8–5.3) 8 (1–14) 8 5.2 (2.6–10.4) 14 (2–26)
- Colorectal cancer 16 2.3 (1.4–3.8) 8 (1–15) 6 2.4 (1.1–5.4) 3 (21–7) 5 5.6 (2.3–13.5) 9 (21–18)
 Respiratory system and
intrathoracic organs
31 3.3 (2.3–4.7) 19 (10–29) 9 2.8 (1.4–5.3) 5 (0–10) 13 11.5 (6.7–20.0) 26 (10–41)
- Cancer of lung, bronchus
and trachea
28 3.3 (2.3–4.8) 17 (8–27) 8 2.8 (1.4–5.6) 4 (0–9) 13 13.4 (7.8–23.2) 26 (11–41)
 Mesothelioma and connective
tissue
10 13.2 (7.0–24.8) 8 (3–14) 2 4.9 (1.2–19.9) 1 (21–4) 2 13.1 (3.2–52.7) 4 (22–10)
- Mesothelioma 5 21.7 (8.8–53.5) 4 (0–8) 0 – – 0 – –
 Breast 38 4.1 (3.0–5.6) 26 (15–38) 22 3.8 (2.5–5.9) 14 (6–22) 9 5.2 (2.7–9.9) 16 (3–28)
 Lymphatic and haematopoietic
tissue
20 4.6 (2.9–7.1) 14 (6–22) 5 2.0 (0.8–4.9) 2 (22–6) 4 4.2 (1.6–11.2) 7 (22–15)
- Non-Hodgkin lymphoma 10 5.6 (3.0–10.4) 7 (2–13) 2 1.8 (0.5–7.4) 1 (22–3) 0 – –
- Leukaemia 9 5.7 (3.0–11.1) 7 (1–12) 2 2.6 (0.7–10.6) 1 (21–3) 3 10.7 (3.4–33.3) 6 (21–13)
Nonmalignant haematological
conditions
22 2.6 (1.7–3.9) 12 (4–20) 17 3.1 (1.9–5.0) 10 (3–17) 20 9.7 (6.2–15.0) 39 (20–57)
Diseases of nervous system and
sense organs
48 1.7 (1.3–2.3) 18 (6–30) 35 1.5 (1.1–2.1) 10 (0–20) 21 2.3 (1.5–3.5) 25 (6–45)
 Bacterial meningitis 6 9.5 (4.2–21.5) 5 (1–9) 5 16.4 (6.7–40.3) 4 (0–8) 3 23.1 (7.4–72.8) 6 (21–13)
Circulatory system 458 2.7 (2.5–3.0) 259 (221–297) 167 1.8 (1.6–2.1) 66 (44–88) 129 3.6 (3.1–4.3) 201 (153–249)
 Angina pectoris 46 2.6 (2.0–3.5) 26 (14–39) 18 1.8 (1.1–2.9) 7 (0–14) 16 4.3 (2.6–7.1) 27 (10–45)
 Acute myocardial infarction 53 2.9 (2.2–3.8) 32 (19–45) 14 1.7 (1.0–2.9) 5 (21–12) 15 4.7 (2.8–7.7) 26 (9–42)
 Chronic ischemic heart
disease
35 3.5 (2.5–4.9) 23 (12–33) 13 3.0 (1.7–5.2) 8 (1–14) 10 6.0 (3.2–11.1) 18 (5–32)
 Mitral valve disorders 12 11.5 (6.5–20.4) 10 (4–16) 4 9.9 (3.7–26.9) 3 (0–7) 1 6.4 (0.9–45.7) 2 (22–6)
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Table 4. The cohort of 1,768 five-year survivors of Hodgkin lymphoma diagnosed in adolescence or young adulthood divided into three subcohorts (Continued)
Survivors of Hodgkin lymphoma
diagnosed 1943–1976
Survivors of Hodgkin lymphoma
diagnosed 1977–2004
Early mixed
subcohort1
Primary treatment
only subcohort2
Assumed relapse
subcohort3
No. of
new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
No. of
new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
No. of new
diagnoses
obs.
RR
(95% CI)
AER4
(95% CI)
 Aortic valve disorders 44 24.7 (18.2–33.5) 38 (27–50) 14 18.4 (10.7–31.4) 12 (5–18) 10 34.9 (18.6–65.7) 21 (8–34)
 Heart failure 36 7.1 (5.1–9.9) 28 (17–39) 14 6.2 (3.6–10.5) 10 (4–17) 3 3.4 (1.1–10.7) 5 (23–12)
Respiratory system 171 2.6 (2.3–3.0) 95 (72–118) 98 2.0 (1.6–2.4) 42 (25–59) 103 5.3 (4.4–6.4) 179 (137–222)
 Pneumonia 57 3.0 (2.3–3.9) 35 (21–49) 35 2.6 (1.9–3.7) 19 (9–29) 40 8.0 (5.8–10.9) 78 (50–105)
Digestive organs 188 1.6 (1.4–1.8) 61 (37–85) 88 0.9 (0.7–1.1) –10 (–26–6) 87 2.2 (1.8–2.7) 101 (62–141)
Urinary system and
genital organs
118 1.1 (0.9–1.3) 10 (–9–29) 86 1.1 (0.9–1.4) 7 (–9–22) 54 1.8 (1.4–2.4) 53 (22–84)
 Renal failure 9 4.0 (2.1–7.7) 6 (1–11) 3 1.9 (0.6–6.0) 1 (22–4) 5 8.4 (3.5–20.2) 9 (0–19)
Special calculations for
infections
 Infections classified in
other ICD-chapters5
109 2.5 (2.0–3.0) 58 (40–76) 84 2.2 (1.8–2.7) 40 (24–55) 83 5.5 (4.4–6.8) 146 (107–184)
 All infections6 172 2.5 (2.2–2.9) 93 (70–116) 137 2.2 (1.8–2.6) 64 (44–84) 133 5.3 (4.5–6.3) 232 (183–280)
Rate ratios (RRs) and absolute excess rates (AERs) with corresponding 95% confidence intervals (CIs) are given for selected main diagnostic groups and for selected specific disease categories.
1No information on rehospitalisations available.
2No rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncological or haematological department one year or more after the first Hodgkin lymphoma diagnosis or, if rehospitalised
for Hodgkin lymphoma 6 months to one year after the first Hodgkin lymphoma diagnosis, did not die within 10 years after the first Hodgkin lymphoma diagnosis.
3Rehospitalisation with Hodgkin lymphoma as primary diagnosis in an oncologic or haematologic department one year or more after the first Hodgkin lymphoma diagnosis, or rehospitalisation 6
months to one year after the first Hodgkin lymphoma diagnosis and deceased within 10 years of the first Hodgkin lymphoma diagnosis.
4Absolute excess rate per 10,000 person-years; the rates are standardised for age, sex and calendar periods.
5From Nervous system and sense organs: bacterial meningitis, encephalitis, myelitis and encephalomyelitis and intracranial and intraspinal abscess; from Circulatory system: Acute and subacute
endocarditis; from Respiratory system: Acute upper respiratory infections, pneumonia, other acute lower respiratory infections, bronchitis, abscess of lung and pleural empyema; from Digestive
organs: acute peritonitis; from Skin and subcutaneous tissue: cutaneous abscess, furuncle and carbuncle, cellulitis, other infections of skin and subcutaneous tissue; from Musculoskeletal and con-
nective tissue: infectious arthropathies, from Urinary and genital organs: cystitis.
6The sum of infections classified in the ICD chapter ‘Infections’ and infections classified in other ICD chapters.
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Figure 3. (a) Rate ratios (RRs) for bed-days for selected main diagnostic groups with estimates for each of the three subcohorts. (b) Abso-
lute excess rates (AERs) for bed-days for selected main diagnostic groups per 10,000 person-years for each of the three subcohorts. The
total AERs (not included in the plot) are:- for those diagnosed 1943–1976 (i.e., early mixed subcohort): 20,520, 95% CI, 20,205–20,836;
for those diagnosed 1977–2004 and with no rehospitalisations (i.e., primary treatment only subcohort): 3,384, 95% CI, 3,226–3,542; for
those diagnosed 1977–2004 and with rehospitalisations (i.e., assumed relapse subcohort): 37,070, 95% CI, 36,489–37,652. [Color figure
can be viewed at wileyonlinelibrary.com]
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the proportional increases in the bed-day rates were highest
for the 1977–2004 assumed relapse subcohort, followed by the
early mixed subcohort and then the primary treatment only
subcohort (Fig. 3, panel A). The largest AERs for bed-days
were for malignant neoplasms, circulatory diseases and all
infections combined, with a pattern between the three subco-
horts similar to that seen for the RRs (Fig. 3, panel B). The
many extra bed-days among survivors of Hodgkin lymphoma
were mainly due to more frequent hospitalisations rather than
hospitalisations over longer periods.
Among the 887 survivors diagnosed during 1977–2004
and with no readmission to hospital for Hodgkin lymphoma,
494 only received chemotherapy as judged from the records
of the Cancer Registry while 338 survivors also received
radiotherapy, and the overall rate ratios for hospitalisation in
these two groups were 1.3 (95% CI,1.2–1.4) and 1.6 (1.4–1.7),
respectively. Ratios also tended to be higher in the group
who received both radiotherapy and chemotherapy for the
main diagnostic groups of malignant neoplasms (RR, 3.0 vs.
2.0), nonmalignant haematological conditions (4.0 vs. 2.3),
diseases of circulatory system (2.1 vs. 1.6) and diseases of
respiratory system (2.5 vs. 1.5), although none of the differ-
ences was statistically signiﬁcant.
Discussion
In this population-based long-term follow-up study of 1,768
ﬁve-year survivors of Hodgkin lymphoma diagnosed in ado-
lescence or young adulthood in Denmark, survivors received
new diagnoses requiring hospitalisation signiﬁcantly more
often than the general population, and survivors spent more
days in hospital. The increased burden of disease affected
both men and women and was lifelong and particularly
heavy for patients readmitted to hospital for Hodgkin lym-
phoma and who are likely to have had a relapse. Thus, for
example, among patients aged 50–59 years diagnosed in
1977–2004 and readmitted to hospital for an assumed relapse
15 in 100 experienced a new disease requiring inpatient care
each year. The equivalent estimate in the primary treatment
only subcohort was 5 in 100. All main diagnostic groups
were affected but diseases of the circulatory system, all infec-
tions combined, and malignant neoplasms explained together
between 61% and 78% of the excess new diagnoses depend-
ing on the subcohort of survivors.
To our knowledge, the present study is the ﬁrst to
describe the long-term risks of hospitalisation for the full
spectrum of physical diseases in survivors of Hodgkin lym-
phoma diagnosed in adolescence or young adulthood in a
large population. One other study has done so18 but, as it
was based on only 281 individuals, it was unable to provide
risk estimates with any precision. Several studies of cause-
speciﬁc mortality in survivors of Hodgkin lymphoma diag-
nosed in childhood or early adult life have been carried
out,19–21 and the risk of hospitalisation among survivors of
all types of cancer diagnosed in adolescence and young adult-
hood has been studied in other populations.22–25 Other
studies speciﬁcally of survivors of Hodgkin lymphoma diag-
nosed in young adulthood have usually reported on speciﬁc
risks of second cancers11,26–33 or cardiovascular dis-
eases.12,34–36 The results of our study are in agreement with
their ﬁndings. In particular, we found substantial proportion-
al increases in the incidence of aortic valve disease and of
female breast cancer. Our study is, however, the ﬁrst large
study that has been able to quantify the burden of different
diseases and compare them. We have shown that, while car-
diovascular disease is responsible for by far the largest num-
ber of new diagnoses, by far the largest number of days spent
in hospital are attributable to cancer. Our study has also, for
the ﬁrst time, revealed the importance of infections as a late
effect of Hodgkin lymphoma, both in terms of numbers of
new diagnoses and in terms of time spent in hospital (Figs. 2
and 3). Several other studies have reported increases in inci-
dence or mortality from infections either in survivors of
Hodgkin lymphoma,9,18 or in broader groups of cancers diag-
nosed in teenagers and young adults22,24,25 but none of these
studies has revealed the extent of the disease burden from
infections, as they have all considered only infections classi-
ﬁed in Chapter II of the ICD, rather than bringing together
all infections irrespective of where they appear in the ICD.
We included patients treated over a time period of 60
years during which time the treatment for Hodgkin lympho-
ma has evolved dramatically. The treatments used in Den-
mark during this time period are similar to those used in
other developed countries. In the period 1943–1964 radio-
therapy was the mainstay of treatment for Hodgkin lympho-
ma; initially given as palliative treatment, although later as
intended curative treatment in the form of total or subtotal
nodal radiotherapy.37 In the period 1965–1980 radiotherapy
was still the primary treatment but now with adjuvant che-
motherapy. Around 1980 chemotherapy became the primary
treatment, with radiotherapy as consolidating treatment.
From approximately 1970, the mustargen–oncovin–procarba-
zine–prednisone (MOPP) regime was used; however, a gradu-
al shift to an adriamycin–bleomycin–vinblastine–dacarbazine
(ABVD) regime took place around 1985. Without systemic
treatment, the risk of relapse and the need for further treat-
ment was much higher than in the more recent period, when
combination treatment with chemotherapy became the stan-
dard. Thus the subsequent morbidity of many patients previ-
ously treated for Hodgkin lymphoma with radiotherapy alone
was heavily inﬂuenced by intensive chemotherapy and per-
haps further radiotherapy given for relapse. As this study
lacks individual and detailed treatment data, we cannot draw
any conclusions regarding the speciﬁc links between types of
treatment and risks of physical disease. However, for the sub-
cohort of survivors diagnosed during 1977–2004, we saw a
tendency for higher risks among those registered in the Dan-
ish Cancer Registry as treated with radiotherapy compared to
those registered without.
The prospective nature of this study, with virtually com-
plete registration of cases of Hodgkin lymphoma in
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adolescence and young adulthood prior to, and independent-
ly of, the recording of subsequent hospital admissions, elimi-
nates the possibility of selection bias and differential
reporting. However, our study also has some important limi-
tations. Conditions such as less severe late effects that are
treated exclusively in outpatient clinics or in the primary
healthcare system, will not have been included, implying that
the total burden of physical disease experienced by Hodgkin
lymphoma survivors may be somewhat underestimated. On
the other hand, the diseases included in our study represent
the most severe segment of late effects, which are also the
most important ones to consider when planning programmes
for surveillance and intervention. We cannot exclude the pos-
sibility that surveillance bias affects our study, since the
health professional’s knowledge about their patient being a
survivor of Hodgkin lymphoma might inﬂuence their deci-
sions on whether to hospitalise. This might have led to an
unknown degree of overestimation of the reported risk
estimates.
We applied a large set of statistical tests on the material,
which implies that on average one out of 20 ﬁndings may be
false positive. However, our survey should not be regarded as
a study testing a speciﬁc hypothesis but rather a study
describing a wide range of potential late effects in ﬁve-year
survivors of Hodgkin lymphoma.
Follow-up programmes have also changed dramatically
over the period. Since 2000, survivors of Hodgkin lymphoma
in Denmark are followed approximately every fourth month
during the ﬁrst two years after the end of treatment and
thereafter approximately twice a year until ﬁve years after the
end of treatment. Before 2000, the norm was follow-up visits
twice a year 10 years after the end of treatment; at these vis-
its scans were performed to detect any abnormalities; nowa-
days scans are primarily performed when the survivor
reports symptoms which could indicate abnormalities or give
suspicions about relapse.
Survivors of Hodgkin lymphoma diagnosed in adolescence
or young adulthood are at increased risk for a wide range of
physical diseases severe enough to require hospitalisation.
This study is the ﬁrst to quantify the burden of the full spec-
trum of physical diseases suffered by this population. Howev-
er, research is needed to conﬁrm the assumption that
screening, surveillance and intervention among Hodgkin lym-
phoma survivors can be effective in detecting and modifying
the course of diseases that occur as a result of their previous
diagnosis and treatment. If the efﬁcacy of such programs can
be demonstrated and they can be implemented in a cost-
effective manner, then the considerable burden of disease
quantiﬁed in this study could be reduced and the potential to
improve both the quality and length of life for Hodgkin lym-
phoma survivors would be substantial.
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